Abstract

Poly-ICLC molecules and methods for producing them, including certain specific molecular weight molecules having improved activity in certain applications. These molecules may be incorporated in pharmaceutically or veterinary acceptable excipients and carriers for a number of uses in humans, in domestic animals and in wild animals. Such uses include (but are not limited to) prophylaxis pre-exposure prophylaxis, treatment and/or inflammatory symptom attenuation of viral or microbial infections; immunomodulating, vaccine adjuvant, antiviral, and/or anti-inflammatory effects mediated through activation of the MDA5, TLR3 and other dsRNA dependent enzyme systems; antineoplastic effects either alone or when combined with therapeutic vaccine or other anticancer immunologic agents; preventive cancer vaccine adjuvant effects in patients at risk for cancer. The molecules may be of particular use against SARS-CoV-2 infection or a cytokine storm caused by a SARS-CoV-2 infection. While dosage may be adjusted depending on the specific target and the specific patient, the dose should be sufficient to activate the MDA5 and TLR3 enzyme systems in the patient. For humans the dose is between approximately 0.5 and 50 micrograms per kilogram body weight. The nature of the molecule does not demand any specific route of administration. Therefore, the route can be selected based on the specific target and the specific patient, and could include (but not be limited to) IM, SC, IT, IV or IN. Preferably, administration would comprise two or three repeated dose cycles spaced 24 to 96 hours apart. Depending on the target and the patient's response, dose cycles may be repeated 2 to 4 times per month.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61P 31/14 - Antivirals for RNA viruses
• A61P 35/00 - Antineoplastic agents

Abstract

A scalable process for production of polyribonucleotides of controlled molecular weight range through variation of processing time and input concentrations. Key elements include a method for immobilization of polynucleotide phosphorylase which has been covalently attached to an amino-functionalized solid support via a glutaraldehyde linkage; a method of repeatedly reacting inosine diphosphate or cytidine diphosphate monomer s with immobilized polynucleotide phosphorylase to produce polyribonucleotide chains; control of the chain length of Poly(I) and Poly (C) by varying cofactor concentration and the length of reaction time; a method for controlled and efficient large-scale manufacture of a specific, determined range of molecular weight poly I and poly C homopolymer chains.

IPC Classes  ?

• C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
• C12N 11/087 - Acrylic polymers

Abstract

Poly-ICLC molecules and methods for producing them, including certain specific molecular weight molecules having improved activity in certain applications. These molecules may be incorporated in pharmaceutically or veterinary acceptable excipients and carriers for a number of uses in humans, in domestic animals and in wild animals. Such uses include (but are not limited to) prophylaxis pre-exposure prophylaxis, treatment and/or inflammatory symptom attenuation of viral or microbial infections; immunomodulating, vaccine adjuvant, antiviral, and/or anti-inflammatory effects mediated through activation of the MDA5, TLR3 and other dsRNA dependent enzyme systems; antineoplastic effects either alone or when combined with therapeutic vaccine or other anticancer immunologic agents; preventive cancer vaccine adjuvant effects in patients at risk for cancer. The molecules may be of particular use against SARS-CoV-2 infection or a cytokine storm caused by a SARS-CoV-2 infection. While dosage may be adjusted depending on the specific target and the specific patient, the dose should be sufficient to activate the MDA5 and TLR3 enzyme systems in the patient. For humans the dose is between approximately 0.5 and 50 micrograms per kilogram body weight. The nature of the molecule does not demand any specific route of administration. Therefore, the route can be selected based on the specific target and the specific patient, and could include (but not be limited to) IM, SC, IT, IV or IN. Preferably, administration would comprise two or three repeated dose cycles spaced 24 to 96 hours apart. Depending on the target and the patient's response, dose cycles may be repeated 2 to 4 times per month.

IPC Classes  ?

• C12N 11/08 - Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
• A61K 9/14 - Particulate form, e.g. powders
• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants

Abstract

The containment of accidental or intentional epidemic disease outbreaks of pathogens to which our populations have limited or no immunity has thus become one of the principal public health challenges of our time. Methods for clinical administration of pharmaceutical compounds for prevention and attenuation of the inflammatory response to microbial diseases, particularly to the use of double stranded ribonucleic acids (dsRNA). Polyriboinosinic- polyribocytidylic acid stabilized with polylysine and carboxymethylcellulose (Poly-ICLC) converts a virus into the equivalent of an attenuated live-microbe vaccine specific to that microbe, so that Poly-ICLC significantly diminishes infectivity if administered appropriately following infection.

IPC Classes  ?

• A61K 31/716 - Glucans
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

A scalable process for production of polyribonucleotides of controlled molecular weight range through variation of processing time and input concentrations. Key elements include a method for immobilization of polynucleotide phosphorylase which has been covalently attached to an amino-functionalized solid support via a glutaraldehyde linkage; a method of repeatedly reacting inosine diphosphate or cytidine diphosphate monomer s with immobilized polynucleotide phosphorylase to produce polyribonucleotide chains; control of the chain length of Poly(I) and Poly(C) by varying cofactor concentration and the length of reaction time; a method for controlled and efficient large-scale manufacture of a specific, determined range of molecular weight poly I and poly C homopolymer chains.

IPC Classes  ?

• C12N 11/087 - Acrylic polymers
• C12N 11/02 - Enzymes or microbial cells immobilised on or in an organic carrier
• C12N 11/08 - Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
• C12N 11/06 - Enzymes or microbial cells immobilised on or in an organic carrier attached to the carrier via a bridging agent
• C12P 19/30 - Nucleotides
• C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides

Goods & Services

Pharmaceuticals for treatment of viral and oncological disease

Goods & Services

Pharmaceuticals for the treatment of cancer and viral diseases